The apoptosis-resistance in t-AUCB-treated glioblastoma cells depends on activation of Hsp27

Journal of Neuro-Oncology

Volumn 110, Issue 2, 2012, Pages 187-194

  Li, Junyang ^a   Hu, Weixing ^b   Lan, Qing ^a  

^a SOOCHOW UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Glioma; Heat shock protein 27; Inhibitor; Resistance; Soluble epoxide hydrolase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 [3 (1 ADAMANTYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; ANISOMYCIN; ANTINEOPLASTIC AGENT; CASPASE 3; HEAT SHOCK PROTEIN 27; KRIBB3; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMORESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PHYSICAL SENSITIVITY; TUMOR CELL; TUMOR CELL CULTURE;

APOPTOSIS; BENZOATES; BLOTTING, WESTERN; BRAIN NEOPLASMS; CASPASE 3; CELL PROLIFERATION; ENZYME INHIBITORS; EPOXIDE HYDROLASES; FLOW CYTOMETRY; GLIOBLASTOMA; HSP27 HEAT-SHOCK PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; TUMOR CELLS, CULTURED; UREA;

EID: 84867843684     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0963-8     Document Type: Article

References (25)

1. Edin ML, Wang Z, Bradbury JA, Graves JP, Lih FB, DeGraff LM, Foley JF, Torphy R, Ronnekleiv OK, Tomer KB, Lee CR, Zeldin DC (2011) Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J 25:3436-3447. doi: 10.1096/fj.11-188300
2. Merabet N, Bellien J, Glevarec E, Nicol L, Lucas D, Remy-Jouet I, Bounoure F, Dreano Y, Wecker D, Thuillez C, Mulder P (2012) Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure. J Mol Cell Cardiol 52:660-666. doi: 10.1016/j.yjmcc.2011.11.015
3. Davis BB, Liu JY, Tancredi DJ, Wang L, Simon SI, Hammock BD, Pinkerton KE (2011) The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment. Biochem Biophys Res Commun 410:494-500. doi: 10.1016/j.bbrc.2011.06.008
4. Panigrahy D, Kaipainen A, Greene ER, Huang S (2010) Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metast Rev 29:723-735. doi: 10.1007/s10555-010-9264-x
5. Chaudhary KR, Abukhashim M, Hwang SH, Hammock BD, Seubert JM (2010) Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido)- cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury. J Cardiovasc Pharmacol 55:67-73. doi: 10.1097/FJC.0b013e3181c37d69
6. Liu JY, Tsai HJ, Hwang SH, Jones PD, Morisseau C, Hammock BD (2009) Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol 156:284-296. doi: 10.1111/j.1476-5381.2008.00009.x
7. Li J, Liu H, Xing B, Yu Y, Wang H, Chen G, Gu B, Zhang G, Wei D, Gu P, Li M, Hu W (2012) t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-kappaB-p65. J Neurooncol 108:385-393. doi: 10.1007/s11060-012-0841-4
8. Concannon CG, Gorman AM, Samali A (2003) On the role of Hsp27 in regulating apoptosis. Apoptosis 8:61-70. doi: 10.1023/A:10216011030
9. Hsu HS, Lin JH, Huang WC, Hsu TW, Su K, Chiou SH, Tsai YT, Hung SC (2011) Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer 117:1516-1528. doi: 10.1002/cncr.25599
10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
11. Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, Huq MS (2011) Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology group-recursive partitioning analysis in the IMRT and temozolomide era. J Neurooncol 104:339-349. doi: 10.1007/s11060-010-0499-8
12. Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L, Auberdiac P, Thorin J, Pacaut C, Peoc'h M, Nuti C, Schmitt T, Magne N (2012) Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol 106:127-133. doi: 10.1007/s11060-011- 0643-0
13. Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, Osti MF, Maurizi RE (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103:683-691. doi: 10.1007/s11060-010-0446-8
14. Adachi J, Mishima K, Wakiya K, Suzuki T, Fukuoka K, Yanagisawa T, Matsutani M, Sasaki A, Nishikawa R (2012) O(6)-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. J Neurooncol 107:147-153. doi: 10.1007/s11060-011-0721-3
15. Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi ER, Giangaspero F (2011) Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 102:311-316. doi: 10.1007/s11060-010-0324-4
16. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Re C (2010) Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311-322. doi: 10.1007/s11060-009-0031-1
17. Arrigo AP (2007) The cellular networking of mammalian Hsp27 and its functions in the control of protein folding, redox state and apoptosis. Adv Exp Med Biol 594:14-26. doi: 10.1007/978-0-387-39975-1-2
18. Dai S, Jia Y, Wu SL, Isenberg JS, Ridnour LA, Bandle RW, Wink DA, Roberts DD, Karger BL (2008) Comprehensive characterization of heat shock protein 27 phosphorylation in human endothelial cells stimulated by the microbial dithiole thiolutin. J Proteome Res 7:4384-4395. doi: 10.1021/pr800376w
19. Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86-103
20. Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, Kong SY, Lee ES, Jang SG, Yoo BC (2008) Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 8:286. doi: 10.1186/1471-2407-8-286
21. Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH, Van der Zee AG (1999) Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer 84:234-238. doi: 10.1002/(SICI)1097-0215(19990621)84:3<234:AID-IJC6>3.0. CO;2-9
22. King KL, Li AF, Chau GY, Chi CW, Wu CW, Huang CL, Lui WY (2000) Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer 88:2464-2470. doi: 10.1002/1097-0142(20000601)88:11<2464:AID-CNCR6>3.0. CO;2-W
23. Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y, Sun S (2010) miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology 51:1614-1623. doi: 10.1002/hep.23566
24. Golembieski WA, Thomas SL, Schultz CR, Yunker CK, McClung HM, Lemke N, Cazacu S, Barker T, Sage EH, Brodie C, Rempel SA (2008) HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion. Glia 56:1061-1075. doi: 10.1002/glia.20679
25. Schultz CR, Golembieski WA, King DA, Brown SL, Brodie C, Rempel SA (2012) Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Mol Cancer 11:20. doi: 10.1186/1476-4598-11-20